EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

FLT3-ITD Measurable Residual Disease in Acute Myeloid Leukemia: Implications for FLT3 Inhibitor-Based Therapies

Giorgia Silvestrini, Serena Travaglini iD, Luca Guarnera, Nicole Lelli, Mariadomenica Divona, Elisa Casciani, Sara Ceccolini, Giulia Falconi iD, Tiziana Ottone iD, Maria Teresa Voso iD

Cancers · 11.08.2026 · 18 (16) · 2586

DOI: 10.3390/cancers18162586 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 11.08.2026. Verfasst von Giorgia Silvestrini und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondo Italiano per la Scienza (FIS3), "Amici di Beat Leukemia Dr. Alessandro Cevenini" - ONLUS, “Amici di Beat Leukemia Dr. Alessandro Cevenini”—ONLUS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fms-related receptor tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations occur in approximately 20–25% of patients with acute myeloid leukemia (AML) and are associated with increased relapse risk and inferior survival outcomes. Although measurable residual disease (MRD) has become a key prognostic tool for guiding post-remission treatment decisions, FLT3-ITD was historically considered a suboptimal MRD marker because of its subclonal nature, structural heterogeneity and dynamic behavior during disease evolution. In addition, FLT3-ITD has not yet been fully integrated into routine MRD monitoring due to methodological limitations and a lack of standardized workflows. The latest European LeukemiaNet (ELN)-DAVID 2025 recommendations stressed the use of ultra-high sensitivity (UHS) next-generation sequencing (NGS) technologies to detect FLT3-ITD MRD with improved precision, enabling reliable longitudinal tracking of patient-specific clones at very low variant allele frequencies (VAF). Indeed, despite prospective evidence supporting this approach remaining limited, FLT3-ITD-based MRD monitoring is emerging as a clinically relevant prognostic indicator, contributing to the identification of patients at increased risk of relapse and refining risk stratification, while also informing therapeutic decision-making, particularly in the peri-transplant setting. The present review summarizes the biological underpinnings of FLT3-ITD mutated (FLT3-ITDmut) AML, discusses the methodological challenges of MRD detection, and critically evaluates the evolving role of MRD in refining relapse prediction, supporting post-remission therapy tailoring, and contributing to a harmonized framework for FLT3-ITDmut AML management.

Schlagwörter

Stichwörter der Autor:innen

FLT3 inhibitorsFLT3-ITDFLT3iMRDNGSacute myeloid leukemiaallo-HSCTallogeneic stem-cell transplantationmeasurable residual diseasenext-generation sequencing

Autor:innen und Institutionen

  • Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
  • Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
  • PhD Program in Immunology, Molecular Medicine and Applied Biotechnology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
  • Saint Camillus International University of Health Sciences, 00131 Rome, Italy.
  • Neuro-Oncohematology Unit, Santa Lucia Foundation, Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.), 00143 Rome, Italy.

ORCID-Profile: Serena Travaglini, Giulia Falconi, Tiziana Ottone, Maria Teresa Voso

Förderung

  • Fondo Italiano per la Scienza (FIS3)
  • "Amici di Beat Leukemia Dr. Alessandro Cevenini" - ONLUS
  • “Amici di Beat Leukemia Dr. Alessandro Cevenini”—ONLUS

Zitieren

APA

Silvestrini, G., Travaglini, S., Guarnera, L., Lelli, N., Divona, M., Casciani, E., Ceccolini, S., Falconi, G., Ottone, T., & Voso, M. T. (2026). FLT3-ITD Measurable Residual Disease in Acute Myeloid Leukemia: Implications for FLT3 Inhibitor-Based Therapies. Cancers, 18(16), 2586. https://doi.org/10.3390/cancers18162586

Vancouver

Silvestrini G, Travaglini S, Guarnera L, Lelli N, Divona M, Casciani E, et al. FLT3-ITD Measurable Residual Disease in Acute Myeloid Leukemia: Implications for FLT3 Inhibitor-Based Therapies. Cancers. 2026;18(16):2586. doi:10.3390/cancers18162586

BibTeX
@article{Silvestrini2026,
  author = {Silvestrini, Giorgia and Travaglini, Serena and Guarnera, Luca and Lelli, Nicole and Divona, Mariadomenica and Casciani, Elisa and Ceccolini, Sara and Falconi, Giulia and Ottone, Tiziana and Voso, Maria Teresa},
  title = {FLT3-ITD Measurable Residual Disease in Acute Myeloid Leukemia: Implications for FLT3 Inhibitor-Based Therapies},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {16},
  pages = {2586},
  doi = {10.3390/cancers18162586}
}
Kostenlos starten →